Lb Pharmaceuticals (LBRX) Total Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Current Liabilities history runs 3 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.4 million, down 8.23% from the prior year.
• Total Current Liabilities improved to $10.9 million in Q1 2026 per LBRX's latest filing, from $7.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $10.9 million in Q1 2026 and bottomed at $6.6 million in Q3 2025.
• The 3-year median for Total Current Liabilities is $7.8 million (2024), against an average of $8.3 million.
• Biggest YoY gain for Total Current Liabilities was 8.23% in 2025; the steepest drop was 8.23% in 2025.
• Year by year, Total Current Liabilities stood at $8.1 million in 2024, then dropped by 8.23% to $7.4 million in 2025, then surged by 46.55% to $10.9 million in 2026.
• Per Business Quant, the three latest LBRX Total Current Liabilities figures stand at $10.9 million (Q1 2026), $7.4 million (Q4 2025), and $6.6 million (Q3 2025).